Trial · NCT01394185
Effects of Dronabinol (Oral THC) on Cannabis Use
NCT01394185, Phase 1, Phase 2, Completed, Johns Hopkins University; results first posted 2017-08-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Dronabinol (Oral THC) on Cannabis Use. Trials, record NCT01394185. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01394185
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Dronabinol (Oral THC) on Cannabis Use
- NCT number
- NCT01394185
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 25 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Marijuana Smoking
- Interventions
- Dronabinol 120mg/day, Placebo, Dronabinol 240mg/day
- First posted
- 2011-07-14
- Last updated
- 2017-08-03
- Results first posted
- 2017-08-03
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Marijuana Self-administration - Progressive Ratio | 12-day Dronabinol maintenance period | Participants will be able to self-administer cannabis cigarettes (weighing about 0.8 grams and with about 6% THC) under a progressive ratio schedule. The number of progressive ratios completed (and thus, cannabis cigarettes consumed) is the primary study endpoint |
| Primary | Marijuana Self-administration - Drug Vs Money Choice | 12-day Dronabinol maintenance period | Participants will be able to self-administer cannabis cigarettes (weighing about 0.8 grams and with about 6% THC) in 5 discrete choices each day between one cannabis cigarette and $1. The number of cannabis cigarettes chosen (and subsequently self-administered) is the primary study endpoint |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Marijuana Self-administration - Progressive Ratio | 12-day Dronabinol maintenance period | Progressive Ratios Completed | MEAN | |
| PRIMARY | Marijuana Self-administration - Drug Vs Money Choice | 12-day Dronabinol maintenance period | Cannabis Cigarettes Chosen | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Marijuana Self-administration - Progressive Ratio | Placebo | 5.2 | Standard Error 0.2 | Progressive Ratios Completed | |
| Marijuana Self-administration - Progressive Ratio | 120mg Dronabinol | 4.5 | Standard Error 0.2 | Progressive Ratios Completed | |
| Marijuana Self-administration - Progressive Ratio | 240mg Dronabinol | 4.4 | Standard Error 0.2 | Progressive Ratios Completed | |
| Marijuana Self-administration - Drug Vs Money Choice | Placebo | 3.5 | Standard Error 0.6 | Cannabis Cigarettes Chosen | |
| Marijuana Self-administration - Drug Vs Money Choice | 120mg Dronabinol | 2.3 | Standard Error 0.4 | Cannabis Cigarettes Chosen | |
| Marijuana Self-administration - Drug Vs Money Choice | 240mg Dronabinol | 2.5 | Standard Error 0.5 | Cannabis Cigarettes Chosen |
Source ClinicalTrials.gov
Participant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo, 120mg, 240mg | 8 | |
| Overall Study | STARTED | 120mg, 240mg, Placebo | 2 | |
| Overall Study | STARTED | 240mg, 120mg, Placebo | 2 | |
| Overall Study | STARTED | 120mg, Placebo, 240mg | 4 | |
| Overall Study | STARTED | 240mg, Placebo, 120mg | 6 | |
| Overall Study | STARTED | Placebo, 240mg, 120mg | 3 | |
| Overall Study | COMPLETED | Placebo, 120mg, 240mg | 2 | |
| Overall Study | COMPLETED | 120mg, 240mg, Placebo | 2 | |
| Overall Study | COMPLETED | 240mg, 120mg, Placebo | 2 | |
| Overall Study | COMPLETED | 120mg, Placebo, 240mg | 3 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 25 |
| Total, all-cause mortality | 120mg Dronabinol | 0 | 25 |
| Total, all-cause mortality | 240mg Dronabinol | 0 | 25 |
| Total, other adverse events | Placebo | 0 | 25 |
| Total, other adverse events | 120mg Dronabinol | 0 | 25 |
| Total, other adverse events | 240mg Dronabinol | 0 | 25 |
| Total, serious adverse events | Placebo | 0 | 25 |
| Total, serious adverse events | 120mg Dronabinol | 0 | 25 |
| Total, serious adverse events | 240mg Dronabinol | 0 | 25 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA025044 | Efficacy and Safety of Dronabinol (Oral THC) for Treating Cannabis Dependence | VANDREY, RYAN G | JOHNS HOPKINS UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2009 to 2012 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01394185
GET https://conductscience.org/api/trials/v1/NCT01394185/registered